Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Angina (stable) Clear all

Conditions: Stable Angina
Interventions: Decision Aid; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypertension, Chronic Stable Angina, Vasospastic Angina
Interventions: Amlodipine; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Acute Myocardial Infarction, Acute Coronary Syndrome, Stable Angina Pectoris, Percutaneous Coronary Intervention, Heart Failure
Interventions: Center-Based Cardiac Rehab, mHealth, Home-Based Cardiac Rehab; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Coronary Artery Disease
Interventions: PCI with SELUTION SLR DCB, PCI with FDA approved "-limus" DES; Device
Lead sponsor: M.A. Med Alliance S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 65
States / cities: Jonesboro, Arkansas • Chula Vista, California • Los Angeles, California + 54 more

Conditions: Myocardial Ischemia
Interventions: VM202; Biological
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 21 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Chicago, Illinois • Minneapolis, Minnesota

Conditions: Cardiovascular Disease, Stable Angina, Myocardial Infarction, Coronary Artery Disease
Interventions: ticagrelor; Drug
Lead sponsor: LifeBridge Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stable Angina
Interventions: T89(Dantonic); Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Angina, Stable, Chest Pain, Microvascular Angina, Heart Failure
Interventions: Acupuncture, Non-pain related video health education; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 21 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Myocardial Infarction, Percutaneous Coronary Intervention, Coronary Artery Bypass Surgery, Heart Valve Repair or Replacement, Heart Transplant, Left Ventricular Assist Device, Chronic Stable Angina, Chronic Stable Heart Failure
Interventions: Text Messaging Intervention; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Myocardial Infarction, Percutaneous Transluminal Coronary Angioplasty, Coronary Artery Bypass, Stable Angina, Heart Failure, Valve Disease, Heart, Cardiac Rehabilitation, Stent
Interventions: ROMTech Portable Connect; Device
Lead sponsor: ROM Technologies, INC; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Brookfield, Connecticut

Conditions: Percutaneous Coronary Intervention
Interventions: Bivalirudin, Unfractionated heparin; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Stable Angina (SA), Unstable Angina (UA), NSTEMI - Non-ST Segment Elevation MI
Interventions: Non-Fasting, Fasting; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Microvascular Coronary Artery Disease
Interventions: SAR407899, Placebo, Adenosine, Regadenoson, 13N-ammonia, 82Rubidium; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Jacksonville, Florida • Wellington, Florida + 3 more

Conditions: Stable Angina
Interventions: Erenumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Jacksonville, Florida • Miami, Florida • Atlanta, Georgia + 5 more

Conditions: Coronary Artery Disease, Unstable Angina, Angina, Stable, NSTEMI - Non-ST Segment Elevation MI
Interventions: Prophylactic Impella support for a non-emergent PCI; Device
Lead sponsor: Abiomed Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 21
States / cities: Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 18 more

Conditions: Stable Angina, Metabolic Syndrome
Interventions: Ranolazine, Placebo; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Myocardial Infarction, Stable Angina, Coronary Artery Disease
Interventions: Early appointment (within 10 days), Routine referral (at 5 weeks); Behavioral · Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Myocardial Infarction, Heart Failure, Systolic, Heart Valve Diseases, Angina, Stable, Coronary Artery Disease, Heart Transplant
Interventions: In-person cardiac rehabilitation, Telehealth cardiac rehabilitation; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: San Francisco, California • Denver, Colorado • Baltimore, Maryland + 2 more

Conditions: Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
Interventions: Ranolazine, Ranolazine placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 949 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Little Rock, Arkansas • Merced, California • Moreno Valley, California + 17 more

Conditions: Class IV Angina
Interventions: Not listed
Lead sponsor: CryoLife, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Jacksonville, Florida • Nashville, Tennessee

Conditions: Stable Coronary Artery Disease CAD
Interventions: Not listed
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 18 Years and older
Enrollment: 1,246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Stable Angina
Interventions: Capsaicin, Placebo cream; Drug · Other
Lead sponsor: Neal Weintraub; Other
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Myocardial Infarction, Acute Coronary Syndrome, ST-segment Elevation Myocardial Infarction (STEMI), Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Angina, Stable
Interventions: HeartHome; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Angina, Stable, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions: Stepped Care; Other
Lead sponsor: Peter Lindenauer, MD; Other
Eligibility: 60 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Pittsfield, Massachusetts • Springfield, Massachusetts

Search by objective public record fields.

The PCI Choice Trial: a Pilot Randomized Trial of a Decision Aid for Patients With Stable Coronary Artery Disease

Bioequivalency Study of Amlodipine Tablets Under Fasting Conditions

Improving Cardiac Rehabilitation Outcomes Through Mobile Case Management (iCARE)

SELUTION 4 De Novo Small Vessel IDE Trial

Gene Therapy for the Treatment of Chronic Stable Angina

Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI

A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes

Acupuncture for Individuals With Stable Angina

Text Message Intervention to Improve Cardiac Rehab Participation

Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence

Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial

Breaking Fasts Ahead of Cardiac Caths

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)

Restore EF Observational Study

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

Readiness for Behavior Change After a Heart Attack

MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

CardioGenesis Transmyocardial Revascularization 1-Year Follow-Up Study

Angina Prevalence and Provider Evaluation of Angina Relief

Efficacy of Topical Capsaicin Cream for Stable Angina

HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program

Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA